AltPep announces closing $23.150 million Series A investment round
AltPep announces closing $23.150 million Series A investment round, let by Matrix Capital Management with significant participation by Alexandria Venture Investments. In conjunction with the financing,...
View ArticleClik here to view.
Seattle Startup Chases Alzheimer’s with $23 Million Series A
Read BioSpace article: Seattle Startup Chases Alzheimer’s with $23 Million Series A The post Seattle Startup Chases Alzheimer’s with $23 Million Series A appeared first on AltPep.
View ArticleClik here to view.
Alzheimer’s research gets a boost
Bioengineering startup AltPep advances technology for the early detection and treatment of Alzheimer’s and other amyloid diseases. The post Alzheimer’s research gets a boost appeared first on AltPep.
View ArticleInnovation Journeys: Stories of Invention & Discovery at UW: AltPep
Join UW Vice Provost for Innovation & CoMotion Director François Baneyx as he speaks with Dr. Valerie Daggett, Founder & CEO of UW spinoff AltPep (https://www.altpep.com/) and professor of...
View ArticleAltPep Appoints Nancy Hill to Newly Created Position of Chief Product Officer
SEATTLE, WA – AltPep Corporation, a privately held biotechnology company developing early disease-modifying treatments and detection tools for amyloid diseases, today announced that accomplished...
View ArticleAltPep Receives FDA Breakthrough Device Designation for SOBA-AD, A Simple...
Breakthrough designation reinforces the significant potential of SOBA-AD assay to address the unmet need in Alzheimer’s Disease (AD) detection SOBA-AD assay is designed to selectively detect toxic...
View ArticleReview: Amyloid-β Oligomers: Multiple Moving Targets
Review Full Article and Download as a PDF. By Dylan Shea and Valerie Daggett. Biophysica 2022, 2(2), 91-110; https://doi.org/10.3390/biophysica2020010 Received: 7 April 2022 / Revised: 27 April 2022 /...
View ArticleClik here to view.
Seattle startup aiming to detect, treat Alzheimer’s and Parkinson’s disease...
“The news: University of Washington spinout AltPep recently raised $44.4 million, according to a regulatory filing. The company declined to discuss the filing, but founder and CEO Valerie Daggett spoke...
View ArticleClik here to view.
Promising data from large Alzheimer’s study bodes well for this Seattle startup
“Alzheimer’s disease researchers were buoyed by positive data released Tuesday from a large clinical trial of an experimental therapy being developed by Biogen and Eisai. The early data suggest that...
View ArticleFrom Discovery to Design: Toward Early Detection and Treatment of Alzheimer’s...
Lecture at UW on Oct 13, 2022 with Valerie Daggett, AltPep CEO. Learn about her groundbreaking work in Alzheimer’s and other amyloid diseases. The post From Discovery to Design: Toward Early Detection...
View Article